(VIANEWS) – Semler Scientific (SMLR), Taiwan Semiconductor (TSM), Corcept Therapeutics Incorporated (CORT) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Semler Scientific (SMLR)

36.2% sales growth and 76.81% return on equity

Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States.

Semler Scientific’s sales growth this year is expected to be 52.8% and 23.6% for next year.

Year-on-year quarterly revenue growth grew by 124.6%, now sitting on 50.29M for the twelve trailing months.

Volume

Today’s last reported volume for Semler Scientific is 7978 which is 40.66% below its average volume of 13446.

Semler Scientific’s sales growth for the next quarter is 36.2%. The company’s growth estimates for the present quarter and the next is 4.9% and 7.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 76.81%.

Volatility

Semler Scientific’s last day, last week, and last month’s current volatility was 1.86%, 1.58%, and 1.94%, respectively.

Semler Scientific’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.66% (day), 3.59% (last week), and 3.75% (last month), respectively.

Semler Scientific’s Stock Yearly Top and Bottom Value

Semler Scientific’s stock is valued at $129.86 at 11:22 EST, below its 52-week high of $133.54 and way higher than its 52-week low of $52.60.

Semler Scientific’s Moving Average

Semler Scientific’s worth is way higher than its 50-day moving average of $112.06 and way above its 200-day moving average of $111.97.

2. Taiwan Semiconductor (TSM)

21.8% sales growth and 29.84% return on equity

Taiwan Semiconductor Manufacturing Company Limited manufactures and sells integrated circuits and semiconductors.

Taiwan Semiconductor’s sales growth this year is expected to be 24.2% and 34.8% for next year.

Year-on-year quarterly revenue growth grew by 19.8%, now sitting on 1.45T for the twelve trailing months.

Volume

Today’s last reported volume for Taiwan Semiconductor is 2165380 which is 72.78% below its average volume of 7956710.

Taiwan Semiconductor’s sales growth for the next quarter is 21.8%. The company’s growth estimates for the ongoing quarter and the next is 15.6% and 12.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.84%.

Volatility

Taiwan Semiconductor’s last day, last week, and last month’s current volatility was 0.06%, 1.52%, and 0.78%, respectively.

Taiwan Semiconductor’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.06% (day), 2.68% (last week), and 1.85% (last month), respectively.

Taiwan Semiconductor’s Stock Yearly Top and Bottom Value

Taiwan Semiconductor’s stock is valued at $111.22 at 11:22 EST, way under its 52-week high of $142.20 and way higher than its 52-week low of $83.16.

Taiwan Semiconductor’s Moving Average

Taiwan Semiconductor’s value is under its 50-day moving average of $116.45 and below its 200-day moving average of $116.91.

Previous days news about Taiwan Semiconductor(TSM)

  • According to Bloomberg Quint on Tuesday, 5 October, "With shares of leader Taiwan Semiconductor Manufacturing Co. up more than doubling since the darkest days of the Covid-19 pandemic, and nearest rival United Microelectronics Corp. risingalmost five fold, investors ought to be clamoring over GlobalFoundries’ $1 billion offering."
  • According to Bloomberg Quint on Sunday, 3 October, "The rise of Taiwan Semiconductor Manufacturing Co. and Qualcomm Inc. is proof of this. "
  • According to Bloomberg Quint on Sunday, 3 October, "Nowadays, ever-increasing tracts of the world economy rely on the pure wafer foundry market, of which 55% is controlled by the Taiwan Semiconductor Manufacturing Co. Not only does TSMC pick which businessesget the chips they need, and which countries get its new "fab" factories, the company’s leadership has warned nation-states against competitive onshoring, and advised China not to invade:"

3. Corcept Therapeutics Incorporated (CORT)

21.3% sales growth and 19.99% return on equity

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.

Corcept Therapeutics Incorporated’s sales growth this year is anticipated to be 5.3% and 14.7% for next year.

Year-on-year quarterly revenue growth grew by 3.4%, now sitting on 343.09M for the twelve trailing months.

Volume

Today’s last reported volume for Corcept Therapeutics Incorporated is 298193 which is 37.33% below its average volume of 475877.

Corcept Therapeutics Incorporated’s sales growth is a negative 0% for the current quarter and 21.3% for the next. The company’s growth estimates for the current quarter and the next is 17.6% and 10%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.99%.

Volatility

Corcept Therapeutics Incorporated’s last day, last week, and last month’s current volatility was 1.54%, 1.43%, and 0.98%, respectively.

Corcept Therapeutics Incorporated’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.11% (day), 2.32% (last week), and 1.97% (last month), respectively.

Corcept Therapeutics Incorporated’s Stock Yearly Top and Bottom Value

Corcept Therapeutics Incorporated’s stock is valued at $19.54 at 11:22 EST, way below its 52-week high of $31.18 and way higher than its 52-week low of $16.52.

Corcept Therapeutics Incorporated’s Moving Average

Corcept Therapeutics Incorporated’s value is below its 50-day moving average of $20.75 and way below its 200-day moving average of $21.76.

4. LG Display Co, Ltd AMERICAN (LPL)

14.2% sales growth and 10.22% return on equity

LG Display Co., Ltd.

LG Display Co, Ltd AMERICAN’s sales growth this year is anticipated to be 29.9% and 0.8% for next year.

Year-on-year quarterly revenue growth grew by 31.3%, now sitting on 28.05T for the twelve trailing months.

Volume

Today’s last reported volume for LG Display Co, Ltd AMERICAN is 674871 which is 19.89% below its average volume of 842485.

LG Display Co, Ltd AMERICAN’s sales growth for the next quarter is 14.2%. The company’s growth estimates for the ongoing quarter and the next is 1250% and negative -70.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.22%.

Volatility

LG Display Co, Ltd AMERICAN’s last day, last week, and last month’s current volatility was 2.05%, 1.51%, and 2.00%, respectively.

LG Display Co, Ltd AMERICAN’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.99% (day), 2.04% (last week), and 2.20% (last month), respectively.

LG Display Co, Ltd AMERICAN’s Stock Yearly Top and Bottom Value

LG Display Co, Ltd AMERICAN’s stock is valued at $7.79 at 11:22 EST, way under its 52-week high of $12.31 and way higher than its 52-week low of $6.21.

LG Display Co, Ltd AMERICAN’s Moving Average

LG Display Co, Ltd AMERICAN’s worth is under its 50-day moving average of $8.56 and way below its 200-day moving average of $9.90.

5. Johnson & Johnson (JNJ)

10.4% sales growth and 26.81% return on equity

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide.

Johnson & Johnson’s sales growth this year is expected to be 14.1% and 4% for next year.

Year-on-year quarterly revenue growth grew by 27.1%, now sitting on 89.19B for the twelve trailing months.

Volume

Today’s last reported volume for Johnson & Johnson is 1589690 which is 73.41% below its average volume of 5979740.

Johnson & Johnson’s sales growth is a negative 0% for the ongoing quarter and 10.4% for the next. The company’s growth estimates for the current quarter and the next is 7.3% and 19.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.81%.

Volatility

Johnson & Johnson’s last day, last week, and last month’s current volatility was 0.64%, 2.02%, and 0.97%, respectively.

Johnson & Johnson’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.07% (day), 1.41% (last week), and 1.12% (last month), respectively.

Johnson & Johnson’s Stock Yearly Top and Bottom Value

Johnson & Johnson’s stock is valued at $162.19 at 11:22 EST, below its 52-week high of $179.92 and way above its 52-week low of $133.65.

Johnson & Johnson’s Moving Average

Johnson & Johnson’s worth is below its 50-day moving average of $168.47 and under its 200-day moving average of $167.57.

Previous days news about Johnson & Johnson(JNJ)

  • According to Business Insider on Saturday, 2 October, "The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80 percent (CI, 52.2-92.9%) in adults aged 65 and older. ", "None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments."
  • According to Benzinga on Monday, 4 October, "And, when a booster of the Johnson & Johnson COVID-19 vaccine is given, the strength of protection against COVID-19 further increases.", "Why It Matters: Johnson & Johnson would be joiningPfizer Inc. (NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA) in seeking FDA approval for emergency use of COVID-19 vaccine booster shots. "

6. Good Life Advisors, LLC (ABB)

9.8% sales growth and 7.18% return on equity

ABB Ltd manufactures and sells electrification, industrial automation, motion, and robotics and discrete automation products for customers in utilities, industry and transport, and infrastructure worldwide.

Good Life Advisors, LLC’s sales growth this year is expected to be 13.5% and 5.5% for next year.

Year-on-year quarterly revenue growth grew by 21%, now sitting on 28.11B for the twelve trailing months.

Volume

Today’s last reported volume for Good Life Advisors, LLC is 282870 which is 77.53% below its average volume of 1258900.

Good Life Advisors, LLC’s sales growth for the next quarter is 9.8%. The company’s growth estimates for the current quarter and the next is 90.5% and 57.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.18%.

Volatility

Good Life Advisors, LLC’s last day, last week, and last month’s current volatility was 0.33%, 3.43%, and 1.60%, respectively.

Good Life Advisors, LLC’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.43% (day), 1.12% (last week), and 1.08% (last month), respectively.

Good Life Advisors, LLC’s Stock Yearly Top and Bottom Value

Good Life Advisors, LLC’s stock is valued at $33.43 at 11:22 EST, way under its 52-week high of $38.03 and way above its 52-week low of $24.07.

Good Life Advisors, LLC’s Moving Average

Good Life Advisors, LLC’s worth is below its 50-day moving average of $35.97 and below its 200-day moving average of $34.59.

LEAVE A REPLY

Please enter your comment!
Please enter your name here